Novartis Ag Adr (NVS)

11:00 AM

Pharmaceutical Market to Reach USD 3,033.21 Billion by 2034 Driven by Rising Geriatric Population - GlobeNewswire Inc.

11:00 AM

07:20 AM

Novartis' Strong Branded Drug Portfolio Supports Steady Long-Term Growth - Morningstar

07:20 AM

Oct 28, 2025

Novartis completes acquisition of Tourmaline Bio - Novartis

Oct 28, 2025

Oct 28, 2025

Novartis ADR earnings missed by $0.02, revenue topped estimates - Investing.com Nigeria

Oct 28, 2025

Oct 27, 2025

Novartis to acquire Avidity Biosciences in $12B deal - Proactive financial news

Oct 27, 2025

Oct 27, 2025

Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket - Benzinga

Oct 27, 2025

Oct 22, 2025

Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain - Sahm

Oct 22, 2025

Oct 22, 2025

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer - Novartis

Oct 22, 2025

Oct 20, 2025

Will Positive Regulatory Updates Further Boost INCY Stock? - The Globe and Mail

Oct 20, 2025

Oct 17, 2025

Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial - Sahm

Oct 17, 2025

Oct 16, 2025

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity - Sahm

Oct 16, 2025

Oct 16, 2025

Novartis Strengthens Kidney Disease Pipeline With Promising Data - Sahm

Oct 16, 2025

Oct 15, 2025

Next-Generation Targeted Therapies Reshape Precision Oncology Landscape - Sahm

Oct 15, 2025

Oct 14, 2025

Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears - Sahm

Oct 14, 2025

Oct 13, 2025

Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio? - The Globe and Mail

Oct 13, 2025

Oct 11, 2025

UBS Reaffirms Their Hold Rating on Novartis AG (NOVN) - The Globe and Mail

Oct 11, 2025

Oct 08, 2025

Should You Buy Novartis Stock Before October 28? - Barchart.com

Oct 08, 2025

Oct 08, 2025

Barclays Reaffirms Their Sell Rating on Novartis AG (NOVN) - The Globe and Mail

Oct 08, 2025

Oct 04, 2025

2 Surefire Dividend Stocks to Buy for the Long Haul - sharewise.com

Oct 04, 2025

Oct 03, 2025

Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance (NYSE:NVS) - Seeking Alpha

Oct 03, 2025

Sep 30, 2025

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) - Ariva

Sep 30, 2025

Sep 29, 2025

Pharma's Direct-To-Patient Wave Hits Novartis Next - Sahm

Sep 29, 2025

Sep 29, 2025

Novartis announces commencement of tender offer to acquire Tourmaline Bio - Novartis

Sep 29, 2025

Sep 25, 2025

Trump's New Tariff Barrage Targets Drugs, Trucks, Cabinets: President Says Move Will Protect Manufacturers From 'Unfair Outside Competition' - Sahm

Sep 25, 2025

Sep 25, 2025

Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move? - Sahm

Sep 25, 2025

Sep 24, 2025

Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies - Sahm

Sep 24, 2025

Sep 19, 2025

INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream - The Globe and Mail

Sep 19, 2025

Sep 15, 2025

Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments - Sahm

Sep 15, 2025

Sep 13, 2025

Novartis (NVS) was downgraded to a Sell Rating at Goldman Sachs - The Globe and Mail

Sep 13, 2025

Sep 12, 2025

Goldman Sachs Downgrades Novartis (NVS) to Sell Over Risk Concer - GuruFocus

Sep 12, 2025